BAYLOR ST. LUKE'S & DAN L. DUNCAN
COMPREHENSIVE CANCER CENTER

FOURTH ANNUAL **ACUTE HEMATOLOGIC MALIGNANCIES** SYMPOSIUM

Baylor College of Medicine

HMS
Hematologic Malignancy Symposium
Baylor College of Medicine



CHAIR
Gustavo Rivero, MD

CO-CHAIR
Sravanti Teegavarapu, MD

CO-CHAIR
Effrosyni Apostolidou, MD, PhD

LIVE VIRTUAL SYMPOSIUM

SATURDAY MARCH 26, 2022

Poster Sessions • 1:00pm – 1:45pm CST | Presentations • 8:00am – 4:30 pm CST

OncLive®
AN MJH life sciences® BRAND

KEYNOTE SPEAKERS

Lucy A. Godley MD, PhD
The University of Chicago,
Chicago, IL

George Vassiliou, MD, PhD
Wellcome Sanger Institute, University of Cambridge,
Cambridge, UK

Ross L. Levine, MD
Memorial Sloan Kettering Cancer Center,
New York, NY

Pierre Fenaux, MD, PhD
University of Paris,
Paris, FR

David Sallman, MD
H. Lee Moffit Cancer and Research Center,
Tampa Bay, FL

Amy E. DeZern, MD, MHS
The Johns Hopkins University School of Medicine,
Baltimore, MD

Eric Padron, MD
H. Lee Moffit Cancer and Research Center,
Tampa Bay, FL

Gail J. Roboz, MD
Weill Medical College of Cornell University,
New York, NY

Selina M. Luger, MD, FRCPC
University of Pennsylvania-Perelman Center for Advanced Medicine,
Philadelphia, PA

Courtney D. DiNardo, MD, MSCE
The University of Texas, MD Anderson Cancer Center,
Houston, TX

Daniel A. Pollyea, MD, MS
University of Colorado School of Medicine,
Aurora, CO

Eytan M. Stein, MD
Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center,
New York, NY

Alexander Perl, MD
University of Pennsylvania-Perelman Center for Advanced Medicine,
Philadelphia, PA

Elizabeth A. Griffiths, MD
Roswell Park Comprehensive Cancer Center,
Buffalo, NY

Pramila Krishnamurthy, MD
King College
London, UK

NEEDS

This symposium will bring together recognized national and international speakers to address recent advances in diagnosis of myelodysplastic syndrome (MDS) and measurable residual disease [MRD] directed acute myelogenousleukemia (AML) therapy. During our symposium, we will emphasize the need for physicians to combine up-to-date knowledge and technology to efficiently identify "actionable targets" for treatment of AML and MDS patients. Additionally, we expect to gain insight into promising scientific data that would inform therapy efficacy based on AML MRD evaluation. The symposium will provide important novel development in MDS and AML pathogenesis leading to unique opportunity for clinical trial design ideas.

TARGET AUDIENCE

Hematologists, primary care physicians, nurses, nurse practitioners, physician assistants, medical trainees, and students.

EDUCATIONAL OBJECTIVE

At the conclusion of the activity, participants should be able to:

- Integrate complex acute myelogenous leukemia (AML) genomic landscape into therapeutic and diagnostic algorithms
- Describe the role of monoclonal antibodies for treatment of myelodysplasia
- Discuss the current role of targeted therapy in the treatment of acute myelogenous leukemia
- Summarize current epigenetic principles that explain leukemia initiation

EDUCATIONAL METHODS

Lecture and Panel Discussion

ACTIVITY EVALUATION

Evaluation by questionnaire will address program content, presentation, and possible bias.

ACCREDITATION/CREDIT DESIGNATION

Physician

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baylor College of Medicine designates this live activity for a maximum of 5.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

REGISTER TODAY

Scan this code to register

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurse

Cizik School of Nursing UTHealth is an approved provider of continuing nursing education by the Texas Nurses Association-Approver, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. This activity provides 5.25 contact hours on Nursing Continuing Education (CNE).

DISCLOSURE

In order to meet the requirements of the Accreditation Council for Continuing Medical Education (ACCME) it is the policy of Baylor College of Medicine that all individuals who are in a position to control the content of a CME course (course director, planning committee members, and faculty) disclose relevant financial relationships with commercial interests. All identified conflicts of interest are managed to help ensure that the educational material is scientifically based, accurate, and objectively presented. Specific disclosure will be made to the participants prior to the educational course.

Audio or videotaping is prohibited without written permission from the Activity Director and the Division of Continuing Professional Development, Baylor College of Medicine, Houston, Texas.

CLAIMING CREDIT

Physician CME Credit, Nursing, and Other Healthcare Professional Attendance

After the conference, an email will follow from the Baylor College of Medicine Division of Continuing Professional Development with instructions for completing the evaluation and obtaining your CME, Certificate of Attendance, or CE Certificate (if applicable).

For more information, please contact **Christina Velasquez** at **cguerrer@bcm.edu**.